c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

Por Lucas, Claire M., Harris, Robert J., Giannoudis, Athina, Clark, Richard E.
Publicado no Haematologica (2015)

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia

Por Lucas, Claire M., Harris, Robert J., Giannoudis, Athina, McDonald, Elizabeth, Clark, Richard E.
Publicado no Haematologica (2014)

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

Por Giannoudis, Athina, Davies, Andrea, Lucas, Claire M., Harris, Robert J., Pirmohamed, Munir, Clark, Richard E.
Publicado em 2008

Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein

Por Lucas, Claire M., Fagan, Jemma L., Carter, Anthony, Swale, Bryony, Evans, Craig, Clark, Richard E., Harris, Robert J.
Publicado em 2011

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Por Lucas, Claire M., Harris, Robert J., Giannoudis, Athina, Davies, Andrea, Knight, Katy, Watmough, Sarah J., Wang, Lihui, Clark, Richard E.
Publicado em 2009

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

Por Lucas, Claire M., Scott, Laura J., Carmell, Natasha, Holcroft, Alison K., Hills, Robert K., Burnett, Alan K., Clark, Richard E.
Publicado no Blood Adv (2018)